Danni Yu

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

James J. Harding, Víctor Moreno, Yung‐Jue Bang et al. · Clinical Cancer Research · 2021 · 159 citations · Full text

Pharmacy, Oncology, Pharmacology +17

A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty et al. · Molecular Cancer Therapeutics · 2019 · 87 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

Muhammad Wasif Saif, James A. Knost, E. Gabriela Chiorean et al. · Cancer Chemotherapy and Pharmacology · 2016 · 75 citations

Medicine, Immunology, Oncology +16

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Karen A. Autio, Christopher A. Klebanoff, David Schaer et al. · Clinical Cancer Research · 2020 · 67 citations · Full text

Medicine, Immunology, Pharmacology +17

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung et al. · Clinical Cancer Research · 2020 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17